このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Effect of Hyperglycemia on Gastric Emptying Interactions With Pramlintide

2008年1月15日 更新者:Ludwig-Maximilians - University of Munich

The Influence of Ambient Glycemia on the Effect of Pramlintide on Gastric Emptying in Patients With Type 1 Diabetes and Healthy Subjects

• To examine the influence of acute glycaemia (normoglycaemia and hyperglycaemia) on gastric emptying kinetics in patients with type 1 diabetes and non diabetic subjects when treated with subcutaneous (SC) injections of pramlintide.

調査の概要

詳細な説明

Postprandial increases in plasma glucose concentrations are mainly determined by the degree of postprandial suppression of endogenous glucose production and the rate of appearance of the ingested glucose. The latter is predominantly determined by the amount of glucose taken up by the splanchnic bed. Because nutrient absorption depends on gastric nutrient delivery, gastric emptying rate is a key determinant of the early rise of plasma glucose postprandially. At mealtime, the faster the stomach empties the more rapid the rise in plasma glucose. Yet, plasma glucose concentration is a determinant of gastric emptying rate. In non-diabetic subjects, as plasma glucose rises and approaches the upper limit of the normal range (~140 mg/dl), gastric emptying slows. This likely represents a physiological brake mechanism to limit excess delivery of nutrients, thus avoiding excessive appearance of glucose in plasma. In diabetes, abnormally accelerated gastric emptying as well as delayed gastric emptying have been reported. These conflicting data may be explained by differences of ambient glycaemia. In most of these studies undertaken in diabetic subjects these patients were severely hyperglycaemic, thus the reported delayed gastric emptying may be explained by the effect of hyperglycaemia on gastric motility. Indeed, a small number of studies controlled for ambient glycaemia found acceleration of gastric emptying in diabetes and suggest that diabetes manifests with a maladaptive acceleration of gastric emptying likely contributing to excessive postprandial plasma glucose excursions.

The amylin analog pramlintide is a potential new therapeutic that elicits a potent glucose lowering effect in the postprandial period thought to be due to both a suppression of plasma glucagon and a delay of gastric emptying. It is not clear, however, to what extent the pramlintide-induced delay of gastric emptying offsets a potential maladaptive acceleration of gastric emptying in diabetes patients studied under controlled glycemic conditions. In theory, every drug that reduces hyperglycaemia should accelerate gastric emptying and, thereby, minimize its potential effect on postprandial hyperglycaemia. Thus, the drug-induced effect of amylin on gastric motility may be of great advantage by offset the effects of glycemic induced acceleration on gastric emptying.

研究の種類

介入

入学 (実際)

27

段階

  • 適用できない

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年~65年 (大人、高齢者)

健康ボランティアの受け入れ

はい

受講資格のある性別

全て

説明

Inclusion Criteria:

All of the following criteria are to be fulfilled for inclusion of an individual in the study unless the investigator grants an exception:

  • Clinical diagnosis of type 1 diabetes (otherwise healthy) with an HbA1 ≤ 9%, and on a stable insulin treatment for at least 3 months (preferably on pump regimen) prior to screening OR is a healthy individual.
  • 20-40 years of age, inclusive.
  • Understand and sign an informed consent document, communicate with the investigator, and understand and comply with the requirements of the study.
  • Euthyroid, including subjects receiving thyroid replacement therapy.

If female:

  • Is surgically sterilized by hysterectomy; OR
  • Is post-menopausal, as documented by a history of amenorrhea for 6 months and follicle stimulating hormone (FSH) level within the range specified as post-menopausal by the reporting laboratory at screen (post menopausal women on estrogen may enter the study without obtaining an FSH level); OR
  • If of childbearing potential, meets the following criteria:

negative pregnancy test (ß-HCG), regardless of birth control method (including subjects with tubal ligation);

  • Practicing and willing to continue throughout the study the appropriate contraception (defined as oral, injected, or implanted contraceptives for at least 3 months prior to entry, or barrier contraception).
  • Agree to take every precaution to ensure that pregnancy will not occur during the study.

Exclusion Criteria:

  • Individuals meeting any of the following criteria are to be excluded from the study unless the investigator grants an exception:
  • History of severe hypoglycemia.
  • Body mass index (BMI) ≥ 30 kg/m2.
  • Autonomic nerve dysfunction: abnormal result in the cardiovascular parasympathetic and/or sympathetic tests (screening visit).

Hepatic disease:

  • Known hepatic disease or transaminases (GOT, GPT) ≥ 2x above normal values.

Renal disease:

  • Known or serum urea, serum creatinine ≥ 1.5x above normal values
  • Cardiovascular or pulmonary disease:
  • Arterial hypertension
  • Blood pressure >150/95 mmHg at screening in a sitting position)
  • Arterial occlusive disease
  • Known coronary heart disease
  • Abnormal ECG at screening visit.
  • Gastrointestinal disease:
  • Any known structural gastrointestinal disorder,
  • Gastrointestinal surgery except for appendectomy,
  • Symptoms indicating functional or structural upper gastrointestinal disorder (pain, bloating, postprandial fullness, nausea, emesis,
  • Gastroectomy, gastroparesis, lactose intolerance, and diseases known to alter small bowel absorption; e.g., inflammatory bowel disease.

CNS disease:

  • Epilepsy (including subjects with a past history of convulsions associated with hypoglycaemia),
  • Psychiatric illness (including history of eating disorder such as bulimia or anorexia).
  • Autoimmune disease other than thyroid, pernicious anemia, or vitiligo.
  • Malignant disease requiring chemotherapy,
  • Any acute febrile illness within 2 weeks of Screening (Visit 1) with a temperature of 100°F,
  • Currently abusing alcohol or drugs, or have a history of alcohol or drug abuse that in the investigator's opinion could cause the subject to be non-compliant; or have a general history of non-compliance with medications.
  • Receipt of any investigational drug within 90 days of Screening (Visit 1) (prior treatment with pramlintide is permissible).
  • Currently treated with medications known to interfere with gastric emptying such as, but not limited to:

    • Ca2+ channel antagonists, ß-receptor antagonists, prokinetic agents metoclopramide (Reglan®) and cisapride (Propulsid®); and
    • Chronic (more than 10 days within a 6-month period) macrolide antibiotics such as erythromycin and newer derivatives.
  • Currently treated with:

    • Bile acid sequestering resins cholestyramine (Questran®) and colestipol (Colestid®),
    • Systemic steroids,
    • Anti-obesity agents (including orlistat [Xenical®] and sibutramine [Meridia®]),
    • Alpha-glucosidase inhibitors (acarbose [Precose®] and miglitol [Glyset®]) and meglitinides ([Prandin®] and [Starlix®]).

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:診断
  • 割り当て:ランダム化
  • 介入モデル:クロスオーバー割り当て
  • マスキング:独身

武器と介入

参加者グループ / アーム
介入・治療
プラセボコンパレーター:1
Placebo, euglycemia
placebo SC during euglycemia
placebo during hyperglycemia
実験的:2
Pramlintide, euglycemia
pramlintide SC during eglycemia
pramlintide SC during hyperglycemia
プラセボコンパレーター:3
placebo, hyperglycemia
placebo SC during euglycemia
placebo during hyperglycemia
実験的:4
pramlintide, hyperglycemia
pramlintide SC during eglycemia
pramlintide SC during hyperglycemia

この研究は何を測定していますか?

主要な結果の測定

結果測定
時間枠
• To examine the influence of acute glycaemia (normoglycaemia and hyperglycaemia) on gastric emptying kinetics in patients with type 1 diabetes and non diabetic subjects when treated with subcutaneous (SC) injections of pramlintide.
時間枠:2 years
2 years

二次結果の測定

結果測定
時間枠
• Gastric peristalsis derived from high-resolution scintigraphy by means of Fast Fourier Transform (FFT) analysis. • Effects on gastric emptying and on the rate of appearance of ingested glucose appearance, postprandial glucose sequestration, endoge
時間枠:2 years
2 years

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

捜査官

  • 主任研究者:Joerg Schirra, MD、Ludwig-Maximilians-University of Munic

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始

2005年1月1日

一次修了 (実際)

2007年3月1日

研究の完了 (実際)

2007年4月1日

試験登録日

最初に提出

2007年6月19日

QC基準を満たした最初の提出物

2007年6月19日

最初の投稿 (見積もり)

2007年6月21日

学習記録の更新

投稿された最後の更新 (見積もり)

2008年1月16日

QC基準を満たした最後の更新が送信されました

2008年1月15日

最終確認日

2008年1月1日

詳しくは

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する